
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx is attractive fundamentally because its FDA-cleared RenovoCath device is showing rapid commercial traction, with active cancer centers rising from about 12 at the beginning of 2026 to 26 currently, supporting a revenue increase to $1.1 million in fiscal Q3 2026, up 301% year over year. Its TAMP platform and lead RenovoGem program add longer-term upside, since the Phase 3 TIGeR-PaC trial has progressed through a positive second interim review, completed enrollment in August 2026, and remains on track for completion in 1H 2027 with top-line data expected in 2H 2027. The balance sheet also looks manageable with $10 million in cash and no debt, while the cited ~billion dollars market potential and projected 2026/27 revenue growth reinforce the view that the shares are undervalued relative to the opportunity.
Bears say
RenovoRx is a clinical-stage biopharmaceutical company with no established commercial product, leaving its valuation heavily dependent on future trial outcomes and regulatory success rather than recurring revenue. Its prospects are constrained by balance sheet and liquidity risk, and the company still faces significant uncertainty around demonstrating safety and efficacy, securing approvals, and proving it can commercialize its targeted delivery platform. Even if the technology shows promise, reimbursement hurdles, competition, macroeconomic pressure, and weak biotech investor sentiment could limit adoption and financing flexibility, reinforcing a negative fundamental outlook.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About RenovoRx (RNXT) Forecast
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares